Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Open access
Collections
- BA - IGM - Artigos de Periódicos [3831]
- IOC - Artigos de Periódicos [12989]
Metadata
Show full item record
DIFFERENTIAL EXPRESSION OF THE EICOSANOID PATHWAY IN PATIENTS WITH LOCALIZED OR MUCOSAL CUTANEOUS LEISHMANIASIS
Author
Affilliation
Abstract
Unfettered inflammation is thought to play critical role in the development of different clinical forms of tegumentary leishmaniasis. Eicosanoids are potent mediators of inflammation and tightly associated with modulation of immune responses. In this cross-sectional exploratory study, we addressed whether targets from the eicosanoid biosynthetic pathway, assessed by multiplexed expression assays in lesion biopsy and plasma specimens, could highlight a distinct biosignature in patients with mucocutaneous leishmaniasis (MCL) or localized cutaneous leishmaniasis (LCL). Differences in immunopathogenesis between MCL and LCL may result from an imbalance between prostaglandins and leukotrienes, which may serve as targets for future host-directed therapies.
Share